Sign In
Buy TAK
$15.03
-0.150 (-0.99%)
At Close: Jun 03, 2026
Takeda Pharmaceutical Co Ltd (TAK) Shares Fall 4.8% -- GF Value Says Still Overvalued
06:23pm, Monday, 01'st Jun 2026
On June 01, 2026, Takeda Pharmaceutical Co Ltd (TAK) shares fell 4.8% to $15.19. The stock has faced a decline over the past month, with a 1-week drop of 6.5% a
Denali Stock Dips as Biogen-Partnered Parkinson's Disease Study Fails
01:15pm, Friday, 22'nd May 2026
DNLI sinks after BIIB122 failed a mid-stage Parkinson's study, prompting Denali and Biogen to halt development in idiopathic cases.
Attorneys at Hagens Berman Announce $474M Win in Amitiza Jury Trial Against Takeda
05:51pm, Monday, 18'th May 2026
BOSTON--(BUSINESS WIRE)---- $TAK #antitrust--A class-action lawsuit regarding Amitiza ended today when a jury found Takeda Pharmaceuticals liable for $474 million, according to Hagens Berman.
Takeda engaged in antitrust scheme to delay generic constipation drug, US jury finds
02:53pm, Monday, 18'th May 2026
A U.S. jury on Monday found that Takeda Pharmaceutical caused pharmacies, insurers, retailers and others to sustain about $885 million in damages delaying the release
Takeda's Rich Pipeline Optionality Is Worth A 'Buy'
06:29am, Monday, 18'th May 2026
TAK's FY2025 revenue was about $28.4 billion, which was down 1.7% YoY due to Vyvanse's generic pressure. This remains a growth headwind until their first wave launches. Management is pairing a new tra
Takeda Pharmaceutical Q4 Earnings Call Highlights
08:13am, Friday, 15'th May 2026
Takeda Pharmaceutical NYSE: TAK reported fiscal 2025 results that management described as solid despite pressure from generic competition to VYVANSE, while outlining a transition plan built around thr
Takeda to cut about 4,500 jobs in fiscal 2026 as it steps up restructuring
04:49pm, Wednesday, 13'th May 2026
Japan's Takeda Pharmaceutical , plans to cut about 4,500 jobs in fiscal year 2026, as it pushes ahead with a restructuring to centralize corporate functions and reduce costs.
Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results
02:38am, Wednesday, 13'th May 2026
OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for the fiscal year 2025 (period ended March 31, 2026). The Company delivered solid results in line with i
Takeda's immune disease drug meets main goal of mid-to-late stage trial
08:12am, Monday, 04'th May 2026
Takeda Pharmaceutical said its experimental drug for primary immunodeficiency disease, a rare condition that weakens the immune system, has met the main goal of a m
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda announced that TAK-881-3001, a pivotal Phase 2/3 clinical trial in Primary Immunodeficiency Disease (PID) patients, met its primary endpoint.
Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?
10:40am, Thursday, 30'th Apr 2026
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?
03:26pm, Friday, 24'th Apr 2026
ADMA vs. Takeda: surging Asceniv demand boosts ADMA, but Takeda's diversified portfolio and stronger returns make it the steadier pick now.
Assetmark Inc. Buys 33,902 Shares of Takeda Pharmaceutical Co. $TAK
03:24am, Tuesday, 21'st Apr 2026
Assetmark Inc. grew its stake in Takeda Pharmaceutical Co. (NYSE: TAK) by 27.7% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC).
Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?
10:40am, Tuesday, 14'th Apr 2026
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
My Top 4 Pharma Picks Under Rising Geopolitical Risk
12:12pm, Monday, 13'th Apr 2026
Autoimmune diseases, oncology, and type 2 diabetes continue to spread around the world, but these stocks stay off investors' radars. Many of them consistently beat Street's consensus forecasts and off
